Portal de Periódicos da CAPES

Alternative Cellular Energy Based Therapy using Enercel™ in Advanced AIDS Patients Co-infected with Tuberculosis and Treated in Chernigov, Ukraine

2015; MedCrave Group; Volume: 2; Issue: 6 Linguagem: Inglês

10.15406/jhvrv.2015.02.00061

2373-6453

Martin Wj,

Herbal Medicine Research Studies

The therapeutic response of tuberculosis (TB) infected AIDS patients to the administration of Enercel, a registered homeopathic product, was investigated. While all 11 patients in the study received anti-TB medication, only 2 patients received antiretroviral (ARV) drugs. The patients received daily Enercel therapy administered by 4 routes (intravenous, sublingual, intranasal and intrabronchial). Eight of the 11 Enercel treated patients had TB positive sputum smears at the beginning of the study (baseline). The patients receiving Enercel plus ARV became sputum negative at 1 month and those that received Enercel without ARV were sputum negative at 2 months. Clinical and laboratory findings relating to HIV (virus load and CD4 cell counts) improved in all of the Enercel treated patients and especially in the 2 patients receiving combination therapy. The improvements far exceeded those in similar TB infected AIDS patients conventionally treated with ARV and anti-TB medication. Two such patients were included as controls in the present study. One of the control patients not receiving Enercel had negative TB sputum at the start of the study but his sputum became TB positive during the study. The other control patient not receiving Enercel died during the study; as did 6 previously evaluated patients not included in the trial. The benefits to the Enercel treated patients also included a markedly improved quality of life (QOL). This preliminary study is presented to highlight a new, non-toxic approach to the therapy of AIDS patients. The proposed mechanism of action of Enercel is briefly discussed.